Although some early clinical trials have demonstrated the potential of combination therapy with ADCs and ICIs in cancers such as HER-2-positive breast cancer and non-small-cell lung cancer, the inconsistency of effects between different tumor types, as well as the potential for serious adverse events, highlight the need for further optimization of treatment regimens. This evidence concerns the gene ERBB2 and breast carcinoma.